ArticleDiscover oncology2025
Collagen gene signature in the tumor microenvironment predicts survival and guides prognosis in bladder cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- USP5 silencing inhibits the proliferation of bladder cancer cells and induces cell apoptosis and ferroptosis by destabilizing COL14A1 expression.Translational andrology and urology · 2026Article
- Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth.iScience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCollagen, within the tumor microenvironment (TME), assumes a crucial function in the development of cancer. However, the expression of collagen genes in bladder cancer (BCa) remains inadequately comprehended. The aim of this study is to examine the collagen genes expression in the BCa TME, and construct a nomogram to predict the overall survival for patients diagnosed with BCa.
methodsThe Cancer Genome Atlas (TCGA) database (N = 401) and the Gene Expression Omnibus (GEO) database (N = 165) were employed for training and validation cohorts. The correlation between the collagen genes assay and overall survival was investigated using Cox regression analysis. Model construction employed the least absolute shrinkage and selection operator (LASSO) Cox regression algorithm. The model's performance was thoroughly assessed, including its discrimination, calibration, and clinical utility.
resultsThe nomogram, incorporating the P3H4, C1QTNF6, COLGALT1, COL4A1, COL14A1, RGCC, PPARG, SCX and age by utilizing least absolute shrinkage and selection operator Cox regression algorithm, exhibits the favorable predictive capability in the area under the receiver operator characteristic curve, the calibration curve and decision curve analysis. Then, we investigated that C1QTNF6, COL4A1, COL14A1, RGCC and P3H4 were significantly associated with lymph node-positive BCa patients. Additionally, the correlation of collagen genes with tumor mutation burden and immune characteristic was elucidated.
conclusionWe developed a favorable prognostic model using collagen genes, which are potential biomarkers for forecasting the prognosis of BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.